Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
NCT Number: NCT05183087
This is a pilot study to identify biomarkers that individually, and in combination, demonstrate the greatest sensitivity to repetitive, low-level blast exposure (RLLBE) neurotrauma in Special Operations Forces (SOF) personnel. The proposed cross-sectional, multimodal study will elucidate the potential effects of long-term RLLBE by comparing biomarkers across subjects.
Looking for future studies?
Notify Me25 year–45 year
Male
Observational
Boston, Massachusetts, 02114, United States
The proposal includes a comprehensive battery of assessments characterized by high-field neuroimaging, proteomics, and experimental cognitive and neurobehavioral evaluations, which will be implemented alongside standardized clinical diagnostic tools. The results will inform the design of a larger trial to validate the diagnostic utility of these biomarkers as well as their ability to predict RLLBE-related clinical outcomes. A secondary aim will be to define the underlying mechanisms, risk and resilience factors, and clinical phenotypes associated with RLLBE.
Biomarkers assessed over the course of a two-day evaluation will include:
We hypothesize that a multimodal assessment using Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, cognitive/behavioral tests, proteomics and metabolomics will identify biomarkers of RLLBE-related brain injury.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MRI scan of structural connectivity
MRI scan of functional connectivity
PET scan of neuroinflammation
PET scan of tau deposition
Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
Blood-based assessments of proteomic and metabolic biomarkers of brain injury
Time frame: Day 1
measured by white matter tractography
Time frame: Day 2
measured by default mode network connectivity
Time frame: Day 1
measured by standardized uptake value ratio of TSPO ligand [11C]PBR28
Time frame: Day 2
measured by standardized uptake value ratio of [18F]MK6240
Time frame: Day 1, after 6-8 hour fasting
measured by serum concentration of neurofilament light chain
Time frame: Day 1
measured by the Trail Making Test
Time frame: Day 2
measured by the Neurobehavioral Symptom Inventory
Time frame: Day 2
measured by the Neurobehavioral Symptom Inventory
Massachusetts General Hospital
Other
Pilot Study of Long-Term Effects of Repetitive, Low-Level Blast Exposure (RLLBE) on Special Operations Forces (SOF) Service Members
Acronym: ReBlast
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01552473
Barotrauma, Blast Injuries
Dallas, Texas, United States
View Trial DetailsNCT01596569
Barotrauma, Blast Injuries
Boston, Massachusetts, United States
View Trial DetailsNCT01287156
Brain Diseases, Brain Injuries
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05714150
Brain Diseases, Brain Injuries
Gainesville, Florida, United States
View Trial Details